Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228189 | 1.00 | HSD17B10 (0.42) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL2897865 | 1.00 | HSD17B10 (0.42) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL2897864 | 1.00 | HSD17B10 (0.42) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL2894345 | 1.00 | HSD17B10 (0.42) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL2894343 | 1.00 | HSD17B10 (0.42) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL2893902 | 0.95 | HSD17B10 (0.46) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL4561004 | 0.95 | HSD17B10 (0.46) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL2893904 | 0.95 | HSD17B10 (0.46) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL8228626 | 0.95 | HSD17B10 (0.46) | HSD17B10HPGDEPHX1LMNANPSR1 | |
| SCHEMBL2893906 | 0.95 | HSD17B10 (0.46) | HSD17B10HPGDEPHX1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| CN-114555594-B | Substituted azacycles as TRMP modulators | 奇华顿股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | GIVAUDAN SA (CH) | 2024-04-25 | — | — | US | disclosed |
| EP-4045491-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | Givaudan SA (CH) | 2022-08-24 | — | — | EP | disclosed |
| CN-114555594-A | Substituted azaheterocycles as TRMP8 modulators | 奇华顿股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| US-7678796-B2 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2010-03-16 | — | — | US | disclosed |
| WO-2007130820-A2 | MGLUR5 MODULATORS I | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259862-A1 | MGluR5 modulators I | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | HSD17B10 3385/4885HPGD 3732/4885EPHX1 4381/4885 |
| US-20070259862-A1 | MGluR5 modulators I | GRM5, GRM1, GRIK5 | HSD17B10 2742/4885HPGD 2472/4885EPHX1 2134/4885 |
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | HSD17B10 2632/4885HPGD 2431/4885EPHX1 2426/4885 |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | TRPM8, TRPM7, TRPM5 | HSD17B10 3190/4885HPGD 2902/4885EPHX1 3822/4885 |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | HSD17B10 2254/4885HPGD 3427/4885EPHX1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.